Letter to the Editors-in-Chief| Volume 164, P15-16, April 2018

Download started.


Reply to: The effect of bariatric surgery on direct-acting oral anticoagulant drug levels

Published:February 17, 2018DOI:
      Letter to the Editors-in-Chief.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Thrombosis Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y. The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thromb. Res. 2017 Nov 15. PubMed PMID: (29157916).

      2. WHO. WHO obesity and overweight fact sheet no 311 M.

      3. Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. Journal of thrombosis and haemostasis : JTH. 2016 Jun;14(6):1308–13. PubMed PMID: 27299806. Pubmed Central PMCID: PMC4936273.

      4. Kroll D, Stirnimann G, Vogt A, Lai DLL, Borbely YM, Altmeier J, et al. Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery. Br. J. Clin. Pharmacol. 2017 Jul;83(7):1466–75. PubMed PMID: 28121368. Pubmed Central PMCID: PMC5465330.

      5. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin. Pharmacol. Ther. 2005 Oct;78(4):412–21. PubMed PMID: 16198660. (Epub 2005/10/04. eng).

      6. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery. Clin. Pharmacokinet. 2008;47(3):203–16. PubMed PMID: 18307374.

      7. Moore KT, Kroll D. Influences of obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban. Am. J. Med. 2017 Sep;130(9):1024–32. PubMed PMID: 28601546.

      8. Mahlmann A, Gehrisch S, Beyer-Westendorf J. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J. Thromb. Thrombolysis 2013 Feb 17. PubMed PMID: 23417780. (Epub 2013/02/19. Eng).

      9. Cintineo F SL. Plasma concentrations of rivaroxaban after gastric bypass surgery: a case report. Presented at: American Society of Health-System Pharmacists 2015 Midyear Meeting, 2015; New Orleans, Louisiana.

        • Bertaggia-Calderara D.
        • Kröll D.
        • Gerschheimer C.
        • Nicolas N.
        • Nett P.
        • Stirnimann G.
        • Alberio L.
        Effect of rivaroxaban on thrombin generation in vivo. A study in obese patients.
        Int. J. Lab. Hematol. 2018 Feb; 40 (PubMed PMID: 29239121 (Epub 2017 Dec 14)): e11-e14